A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors.
This clinical trial is testing a new experimental medicine called LOXO-783. It is designed for adults with advanced breast cancer or other solid tumour cancers that have spread or cannot be removed with surgery. Researchers are looking specifically for tumours with a gene change known as PIK3CA H1047R. This change can cause cancer cells to grow and divide. Because this is a Phase 1 trial, it is one of the first times LOXO-783 is being given to people. The main goals are to find out if the drug is safe, what side effects it might cause, and to find the best dose to use. Researchers will also look for early signs that the treatment might help shrink or control tumours. Taking part helps doctors learn if this targeted treatment could become a useful option in the future.
At a glance
What is this study about?
Cancers often grow because of changes in the DNA of tumour cells. One well-known change involves a gene called PIK3CA, and specifically a variation known as H1047R. This faulty gene acts like a broken switch, telling cancer cells to keep growing and spreading. This clinical trial is testing a new experimental medicine called LOXO-783, which is designed to specifically target and switch off this faulty signal.
This trial is for people with advanced breast cancer or other solid tumours that carry this exact gene change. 'Advanced' usually means the cancer has spread to other parts of the body or cannot be completely removed with an operation. Doctors hope that by targeting the specific genetic fault, the medicine might help slow down or stop the cancer from growing, while causing fewer effects on healthy cells.
Because this is an early Phase 1 study, it is the first time researchers are testing this drug in humans. The main goal right now is safety. Doctors want to see how the human body handles the medicine, monitor any side effects closely, and work out the safest and most effective dose for future studies.
Key takeaways
- Tests a new targeted drug called LOXO-783 for advanced solid cancers.
- Aimed specifically at tumours with the PIK3CA H1047R gene change.
- This is an early-stage study focusing on safety, side effects, and finding the right dose.
- Requires regular clinic visits for blood tests, health checks, and body scans.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This study is open to adults aged 18 and older who have advanced breast cancer or another type of advanced solid tumour. To take part, your tumour must have been tested and shown to carry the specific PIK3CA H1047R gene change. Your doctor can check past test results or arrange a test to see if your cancer has this feature.
Because this is an early-phase trial, it is generally meant for people whose cancer has not responded to standard treatments, or who have run out of approved treatment options. Participants also need to be reasonably active and well enough to attend regular hospital appointments and take part in daily life.
You may not be eligible if your cancer does not have this specific gene change, if you have other serious medical conditions that could make the trial unsafe, or if you are pregnant or breastfeeding. The trial team will carefully check your overall health and medical history before you can join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with advanced breast cancer or another solid tumour.
- My cancer has been confirmed to have the PIK3CA H1047R genetic change.
- Standard cancer treatments are no longer working, or I have run out of options.
- I am well enough to travel to hospital and attend frequent appointments.
What does participation involve?
Taking part in this study involves regular visits to a specialist hospital or trial clinic. You will receive the study drug, LOXO-783, and the medical team will watch you very closely. At each visit, you can expect health checks such as blood tests, heart scans (ECGs), blood pressure readings, and questions about how you are feeling. You will also have regular imaging scans, like CT or MRI scans, to see how your tumour is responding.
Because this is a first-in-human trial, the first few weeks often require more frequent visits, and you may need to stay at the clinic for several hours on treatment days for extra monitoring. The study continues for as long as the treatment seems to be helping you and you are not having severe side effects. You will also have follow-up visits after stopping the medicine so the team can continue to check on your health.
Potential risks and benefits
Locations (5)
- —UnverifiedBelgium
- —UnverifiedItaly
- —UnverifiedGermany
- —UnverifiedFrance
- —UnverifiedSpain
Common questions
What does 'Phase 1' mean?
A Phase 1 trial is the earliest stage of human testing. It focuses mainly on finding out if a new drug is safe, what side effects it causes, and what dose works best.
How do I know if I have the PIK3CA H1047R mutation?
This is found through a laboratory test on a sample of your tumour tissue or blood. Your oncologist can tell you if your cancer has already been tested for this.
Will I have to pay to take part in this trial?
No, clinical trial medicines and study-related tests are provided free of charge. Some trials also help cover travel expenses to the hospital.
Could I receive a placebo (dummy drug)?
In early Phase 1 cancer studies like this one, placebos are rarely used. All participants are typically given the active trial medicine.
Can I leave the trial if I change my mind?
Yes, taking part is completely voluntary. You can withdraw at any point, and your regular medical team will continue to support you with the best available standard care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.